Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

NCT05156970 PHASE2 COMPLETED

This study is the first clinical study of first-line treatment of head and neck squamous cell carcinoma with drugs targeting VEGF signaling pathway combined with PD-1 inhibitors in China, which explores the new combination therapies urgently needed in clinical practice and lays a foundation for subsequent studies, with important scientific research significance and clinical value.

Details

Lead sponsor	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase	PHASE2
Status	COMPLETED
Enrolment	81
Start date	Thu Jun 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Recurrent Head and Neck Squamous Cell Carcinoma
• Metastatic Head and Neck Squamous Cell Carcinoma

Interventions

• Camrelizumab
• Cisplatin
• Docetaxel
• Apatinib Mesylate
• Carboplatin

Countries

China